国药控股(01099) - 2024 - 中期业绩

Financial Performance - For the six months ended June 30, 2024, the company's revenue was RMB 294,726,810, a decrease of 2.1% compared to RMB 300,950,280 for the same period in 2023[3]. - The net profit attributable to equity holders of the parent company for the same period was RMB 3,703,875, down 9.8% from RMB 4,104,439 in 2023[3]. - Basic and diluted earnings per share were RMB 1.19, compared to RMB 1.32 in the previous year, reflecting a decrease of 9.8%[3]. - The company's gross profit for the period was RMB 21,943,295, a decline of 5.7% from RMB 23,270,681 in 2023[3]. - The company reported a decrease in operating profit to RMB 8,221,630, down 14.2% from RMB 9,581,383 in the previous year[3]. - Total revenue for the six months ended June 30, 2024, was RMB 294,726,810, a slight decrease from RMB 300,950,280 in the same period of 2023, representing a decline of approximately 2.4%[26]. - The operating profit for the group was RMB 10,283,861, compared to RMB 10,283,861 in the previous year, indicating stable performance[26]. - The group reported a net profit of RMB 6,893,231 for the six months ended June 30, 2024, compared to RMB 6,893,231 in the same period of 2023, maintaining profitability[26]. Assets and Liabilities - Total assets increased to RMB 429,583,117 as of June 30, 2024, compared to RMB 383,394,844 at the end of 2023, representing an increase of 12.1%[5]. - The company's total liabilities rose to RMB 307,150,181, up from RMB 263,076,099 at the end of 2023, indicating an increase of 16.8%[7]. - The total assets of the group as of June 30, 2024, were RMB 429,583,117, an increase from RMB 383,394,844 as of December 31, 2023, reflecting growth in asset base[25]. - The total liabilities of the group as of June 30, 2024, were RMB 307,150,181, up from RMB 263,076,099 as of December 31, 2023, indicating increased leverage[25]. - The debt-to-asset ratio rose to 71.50%, an increase of 2.88 percentage points compared to the previous period[61]. - The group's debt-to-asset ratio as of June 30, 2024, was 71.50%, up from 68.62% as of December 31, 2023[82]. Cash Flow and Expenditures - Cash and cash equivalents decreased to RMB 43,331,766 from RMB 63,808,538, a decline of 32.3%[6]. - The company incurred capital expenditures of RMB 2,725,495,000 during the reporting period, with significant investments in property, plant, and equipment[22]. - The group's capital expenditure for the six months ended June 30, 2024, was RMB 2,426,399, compared to RMB 2,426,399 in the previous year, showing continued investment in growth[26]. - The group's capital expenditures for the reporting period were RMB 2,725.50 million, an increase of RMB 1,737.35 million compared to RMB 988.15 million for the six months ended June 30, 2023[78]. Revenue Breakdown - The company reported total revenue of RMB 294,726,810,000 for the six months ended June 30, 2024, with a breakdown of RMB 217,119,317,000 from pharmaceutical distribution, RMB 58,259,633,000 from medical device distribution, RMB 16,242,915,000 from retail pharmacy, and RMB 3,104,945,000 from other businesses[15][16]. - The pharmaceutical distribution segment showed strong performance, contributing the largest share of revenue, indicating a robust market position[15]. - The pharmaceutical distribution segment generated revenue of RMB 226,494.01 million, with a slight increase of 0.47% year-on-year, accounting for 74.10% of total revenue[48]. - The medical device distribution segment reported revenue of RMB 58,494.30 million, a decrease of 7.08% year-on-year, representing 19.14% of total revenue[48]. - The pharmaceutical retail segment's revenue was RMB 16,557.84 million, down 6.43% year-on-year, making up 5.42% of total revenue[48]. Employee and Operational Metrics - The group’s employee benefits expenses for the six months ended June 30, 2024, were RMB 7,211,294, slightly up from RMB 7,151,387 in the previous year, reflecting stable workforce costs[33]. - The total number of employees as of June 30, 2024, was 113,635, an increase from 113,362 as of June 30, 2023[89]. - The group’s depreciation and amortization expenses totaled RMB 2,208,397 for the six months ended June 30, 2024, compared to RMB 2,097,200 in the same period of 2023, indicating increased asset utilization[33]. Financial Management and Strategy - The company recognized a net loss of RMB 179,074,000 from other income and expenses, which included various adjustments and provisions[17]. - The company reported a financial and contract asset expected credit loss of RMB 1,315,125,000, reflecting potential risks in receivables[22]. - The group has established a comprehensive customer credit management system to mitigate credit risk and improve the turnover efficiency of trade receivables[84]. - The company plans to enhance its digital transformation and innovation strategies, focusing on supply chain service transformation to improve business value[58]. - The company aims to strengthen its core competitive advantages and optimize operational quality through digitalization and innovation-driven development strategies[58]. Dividends and Governance - The company proposed a final dividend of RMB 0.87 per share for the year ended 2023, totaling approximately RMB 2,714,971 thousand, which was approved at the annual general meeting[41]. - The company declared a final dividend of approximately RMB 2,714,971 thousand for the year ended December 31, 2023, with no interim dividend proposed for the six months ended June 30, 2024[91]. - The audit committee reviewed the unaudited interim consolidated financial statements for the six months ended June 30, 2024, and agreed with the accounting treatment adopted by the company[92]. - The company has complied with all provisions of the Corporate Governance Code during the reporting period[93].